Alnylam Pharmaceuticals
ALNY
#625
Rank
HK$247.10 B
Marketcap
HK$1,916
Share price
1.06%
Change (1 day)
31.85%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): -HK$1.46 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are HK$2.09 Billion. In 2023 the company made an earning of -HK$2.43 Billion, an increase over its 2022 earnings that were of -HK$7.55 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -HK$1.46 Billion-39.94%
2023 -HK$2.43 Billion-67.84%
2022 -HK$7.55 Billion36.93%
2021 -HK$5.51 Billion-8.04%
2020 -HK$6 Billion-15.66%
2019 -HK$7.11 Billion12.23%
2018 -HK$6.33 Billion62.91%
2017 -HK$3.89 Billion17.78%
2016 -HK$3.3 Billion43.44%
2015 -HK$2.3 Billion60.69%
2014 -HK$1.44 Billion98.2%
2013 -HK$0.73 Billion
2011 -HK$0.43 Billion27.48%
2010 -HK$0.34 Billion-10.92%
2009 -HK$0.38 Billion95.77%
2008 -HK$0.2 Billion
2006 -HK$0.31 Billion-9.13%
2005 -HK$0.34 Billion34.74%
2004 -HK$0.26 Billion36.79%
2003 -HK$0.19 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-HK$4.51 Billion 210.42%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$38.60 B-2,759.15%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$1.00 B-169.24%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$0.92 Billion-36.94%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$0.33 Billion-77.86%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$98.92 B-6,912.96%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
HK$57.55 B-4,063.98%๐Ÿ‡ซ๐Ÿ‡ท France
HK$3.26 B-324.74%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel